noting that, “[b]ecause standing and ripeness pertain to federal courts’ subject matter 12 jurisdiction, they are properly raised in a Rule 12(b)(1) motion to dismiss”
How later courts described this case
- noting that, “[b]ecause standing and ripeness pertain to federal courts’ subject matter 12 jurisdiction, they are properly raised in a Rule 12(b)(1) motion to dismiss”
- substantive due process requires involuntarily committed mental 11 patients to be provide with such services as are necessary to ensure their reasonable safety
Written by the judges who cited it.
The opinion
1
2
3
4 UNITED STATES DISTRICT COURT
5 NORTHERN DISTRICT OF CALIFORNIA
6 EUREKA DIVISION
7
8 VICTOR JIMENEZ, et al., Case No. 23-cv-06353-RMI
9 Plaintiffs,
ORDER RE: PENDING MOTIONS
10 v.
Re: Dkt. Nos. 21, 21, 50
11 U.S. IMMIGRATION AND CUSTOMS
ENFORCEMENT, et al.,
12
Defendants.
13
14 Now pending before the court is Plaintiffs’ First Amended Complaint (“FAC”) (dkt. 68),
15 Plaintiffs’ Motion for Preliminary Injunction (dkt. 20), Plaintiffs’ Motion to Certify Class (dkt.
16 21), and Defendants’ Motion to Dismiss (dkt. 50). The matters have been fully briefed (see dkts.
17 50, 52, 53, 55, 57, 58, 59), and the Parties have presented their positions at oral argument (see dkt.
18 71). For the reasons stated below, Plaintiffs’ motions are denied without prejudice, Defendant’s
19 motion is granted, and the FAC is dismissed with leave to amend.
20 FACTUAL BACKGROUND
21 Plaintiffs Victor Jimenez, Venancio Esteban Riego, and Jose Orozco Cuevas, bring this
22 case on behalf of themselves and other similarly situated persons and claim that Defendants (two
23 named officials of U.S. Immigration and Customs Enforcement) (“ICE”) have failed to provide
24 frequent testing for COVID-19 and antiviral medications to medically vulnerable immigrants
25 detained at the Golden State Annex (or “GSA”). See FAC (dkt. 68) at 1-2. The court takes all of
26 the FAC’s plausible allegations as true. Plaintiffs are medically vulnerable individuals detained at
27 GSA, while they await adjudication of their civil immigration cases. Id. at ¶ 4. Due to the close
1 detention than in the general public. Id. at ¶ 5. In addition to the preventative measures of COVID-
2 19 vaccines, several antiviral treatments have also been developed – Paxlovid and Lagevrio can be
3 taken orally, while Veklury can be taken via intravenous infusion at a healthcare facility. Id. at ¶ 2.
4 Plaintiffs state that “if they were to contract COVID-19, [they] want to receive COVID-19
5 antiviral medications; however, Plaintiffs and others in ICE detention have previously been denied
6 antiviral medications after testing positive for COVID-19.” Id. at ¶ 6.
7 The FAC goes on to state that notwithstanding the fact “that ICE detains a large number of
8 people who are medically vulnerable to serious illness and death from COVID-19, and despite
9 knowing that antiviral medication is critically important to the treatment of COVID-19,
10 Defendants have failed to ensure that people in their custody nationwide can receive antiviral
11 medication in accordance with CDC and National Institutes of Health (“NIH”) guidance.” Id. at ¶
12 7. Defendants have issued post-pandemic guidelines to the effect: that antiviral medication
13 treatment is effective against a particular variant of SARS-CoV-2; that antiviral medication
14 reduces the risk of progression to severe disease; that it decreases the need for hospitalization; and
15 that it reduces the severity of disease thereby improving survival. Id. at ¶ 8. However, rather than
16 dispensing the medicine upon every single positive test, Defendants have only recommended that
17 each detainee newly diagnosed with COVID-19 be assessed for possible antiviral treatment. Id.
18 Plaintiffs allege that this recommendation is insufficient because “people with medical
19 vulnerabilities have tested positive for COVID-19 while held at Golden State Annex and have not
20 been offered COVID-19 antivirals.” Id.
21 Consequently, the FAC alleges that Defendants’ policy of not automatically offering
22 antiviral treatment upon a positive test for COVID-19 to Plaintiffs and the putative class (that is,
23 all civil immigration detainees over the age of 50 who have medical conditions that the CDC
24 recognizes as medically vulnerable to COVID-19) places them at an unreasonable risk of serious
25 illness and death and constitutes an unlawful punishment of the members of the class members. Id.
26 at ¶ 9. Plaintiffs add that the effectiveness of these antiviral medications depends on their prompt
27 administration after symptom onset and requires robust testing and symptom-monitoring protocols
1 Annex. Id. at ¶ 10. Furthermore, they allege that because ICE considers the status at the Golden
2 State Annex to be “green,” the COVID-19 screening protocols are relaxed to only require that
3 individuals detained there receive temperature checks and verbal symptoms screenings during the
4 intake process. Id. If detainees newly admitted to the Golden State Annex are identified with an
5 elevated temperature or COVID-like symptoms, only then are they tested for COVID-19;
6 however, at other facilities designated with a “red” status, all new detainees are tested for COVID-
7 19 at the time of their admission. Id. The ICE “guidelines do not require periodic testing of
8 individuals detained at GSA unless those individuals present with COVID-like symptoms or are
9 determined to have come in contact with an individual who has tested positive for COVID-19.” Id.
10 at ¶ 11.
11 Appearing to narrate anecdotal evidence – but without specifying whether the anecdote
12 refers to any known individuals (including Plaintiffs) or specifying the ultimate outcome of the
13 anecdote – the FAC states that: “even when individuals at the facility have reported symptoms,
14 GSA personnel have ignored the risk that those individuals may have COVID-19, instead
15 suggesting that the symptoms may be for other reasons, like sinus problems[,and] [i]n those
16 instances, medically vulnerable individuals with COVID-19 have waited days, or even weeks,
17 before they were tested for COVID-19, rendering these individuals ineligible for antiviral
18 medication under the CDC and NIH guidelines.” Id. The FAC does not venture to describe
19 anything further about the persons involved in this anecdote – that is, whether their COVID-19
20 tests were positive or negative, whether their illness was mild or severe, or whether the identified
21 symptom was or was not due to sinus problems after all.
22 Plaintiffs then add that “[w]ithout prompt and adequate testing and provision of COVID-
23 19 antiviral medication, Plaintiffs and Class Members lack adequate protection against serious
24 illness and death from COVID-19[, and] [t]his Court should order Defendants to immediately
25 make available and provide Plaintiffs and all similarly situated individuals held at GSA with
26 antiviral medication, by directing GSA to identify medically vulnerable people in Defendants’
27 custody, timely test them for COVID-19, and provide them with antiviral medication upon their
1 As to the medications, Plaintiffs note that Paxlovid has been shown to reduce the risk of
2 COVID-19 hospitalization and death of symptomatic, unvaccinated people who are at high risk for
3 severe COVID-19 by 89%, while reducing the risk of hospitalization for vaccinated individuals or
4 those with prior infections by 51%. Id. at ¶ 27. Those who are unable to take Paxlovid due to a
5 medical complication may be treated with alternatives such as Veklulry (Redemsivir) or Lagevrio
6 (Molnupiravir). Id. at ¶ 28. The FAC alleges that Lagevrio should be taken within five days of
7 symptom onset and Veklury should be taken within seven days of symptom onset. Id. However,
8 the FAC is silent about the potential implications, if any, involved with being administered
9 Paxlovid, Lagevrio, or Veklury later than five or seven days after the onset of symptoms, or
10 whether there would be a difference in cases where the person was vaccinated or unvaccinated, or
11 in cases where the symptoms were mild versus severe.
12 In any event, Plaintiffs allege that these antiviral medicines are widely available, and that
13 the federal government maintains an ample supply “with millions of treatment courses still in the
14 field.” Id. at ¶ 30. Without specifying their vaccination status, Plaintiffs each allege that they are
15 medically vulnerable to severe COVID-19 and face an unreasonable risk of serious illness and
16 death from COVID-19 without the critical treatment option of antiviral medication. Id. at ¶ 31.
17 Plaintiff Jimenez has a history of hypertension and is “currently on five different kinds of
18 medication to treat his cardiovascular issues.” Id. at ¶ 32 Plaintiff Orozco Cuevas also has
19 hypertension; and Plaintiff Riego has hypertension, diabetes, an aneurysm, and dissection of the
20 aorta. Id. at ¶¶ 33-34. The FAC then goes on to generally assert that Defendants are unreasonably
21 and intentionally denying Plaintiffs and class members adequate and timely testing and antiviral
22 medication or COVID-19. Id. at ¶¶ 35-43.
23 Each of the named Plaintiffs then asserts that “[d]espite expressing [their] fears to GSA of
24 contracting COVID-19, GSA facility staff have failed to inform [them] of the availability of
25 antiviral medications in the event [they] contract[] COVID-19[, and therefore] [Plaintiffs] fear[]
26 that if [they] contract[] COVID-19 at GSA, [they] will not be offered antiviral medication.” Id. at
27 ¶¶ 44-46. The FAC then describes the cases of two former GSA detainees – one of whom tested
1 positive but was only provided with cough drops, nasal strips, and electrolyte drinks rather than
2 antiviral medications. Id. at ¶ 47-48. However, the FAC does not describe the experience of these
3 two individuals or the outcome of their illness or course of treatment in any greater detail – that is,
4 it is unknown what symptoms they had, how severe those symptoms were, how long they lasted,
5 whether the symptoms were determined to be related to the positive COVID-19 test, how quickly
6 they recovered, what other medical evaluations were administered, and what course of treatment
7 was determined to be necessary by their care providers and why. Instead, the FAC only complains
8 in general terms that “[o]n multiple occasions, rather than treating individuals with antiviral
9 medications, GSA facility staff only provided detained individuals who tested positive for
10 COVID-19 with water and aspirin, including [the two former detainees mentioned above], who
11 presented with physical symptoms, are medically vulnerable to severe COVID-19, and qualify for
12 antiviral treatment.” Id. at ¶ 49.
13 On the basis of these allegations, the FAC raises two claims. The first claim asserts that the
14 Fifth Amendment due process right of Plaintiffs and the putative class members has been violated
15 in that they have been denied access to adequate medical treatment. Id at ¶¶ 51-55, 69-76. The
16 essence of this claim rests on Plaintiffs’ allegation that “[b]y detaining Plaintiffs and Class
17 Members at GSA without adequate and timely testing and antiviral treatment for COVID-19,
18 Defendants are failing to ensure Plaintiffs’ and Class Members’ reasonable health and safety,
19 exposing them to an increased risk of serious harm from COVID-19, [and] violating their rights
20 under the Fifth Amendment.” Id. at ¶ 71. As to the second claim, the FAC posits that because
21 criminal state detention facilities in California list these antiviral medications as being available to
22 individuals who test positive for COVID-19, and because those medications have not been offered
23 to persons held under civil immigration detention authority at the Golden State Annex, one must
24 conclude that Plaintiffs are being “held in more restrictive conditions than their counterparts in
25 criminal detention” – meaning that Defendants’ failure to ensure Plaintiffs’ automatic access to
26 COVID-19 antiviral treatment when they test positive of COVID-19 necessarily constitutes
27 “punishment” in violation of their substantive due process right. Id. at ¶ 56-58, 77-81. On the
1 motion for class certification (dkt. 21).
2 As attachments to Plaintiffs’ preliminary injunction motion, Plaintiffs have submitted a
3 number of declarations. One Plaintiff stated that during the most recent outbreak, nurses evaluated
4 the temperature and vital signs of the detainees, and when others in his unit tested positive for
5 COVID-19, they would be quarantined away – this Plaintiff stated that he had spoken to those
6 who had tested positive for COVID-19 and they told him that they were only given water and
7 Tylenol and nothing else. See Pls.’ Decl. #1 (dkt. 20-11) at 3-4. Of course, what is missing from
8 this declaration is any indication that the COVID-19 symptoms were not abated by whatever
9 treatment was provided; or whether they had any underlying conditions; or what was the duration
10 or outcome of their experience with COVID-19. Another declaration, from a former Plaintiff,
11 stated that when he tested positive for COVID-19, he was treated (but not with Paxlovid) and
12 quarantined during a period in which he continued to experience a sore throat, muscle pain and
13 shortness of breath; this person also stated that he overheard other detainees requesting a different
14 medicine or to be taken to the hospital, and stated that he did not see any instances where GSA
15 staff addressed those concerns. See Pls. Decl. #2 (dkt. 20-12) at 3-4. However, this declaration
16 suffers from the same shortcomings – the outcomes of the former Plaintiff’s COVID-19
17 experience (as well as the outcomes of the persons whose anecdotes were narrated) are omitted, as
18 are any details about his vaccination status, or any details about the treatment providers’ diagnoses
19 of his symptoms (i.e., whether they were, in fact, related to the positive COVID-19 test). A third
20 declaration submitted by Plaintiffs suffer from the same defects. See Pls. Decl. Nos. #3 (dkt. 20-
21 13). Plaintiffs have also submitted a declaration from Tara Vijayan, M.D., Ph.D., an associate
22 professor of medicine in the infectious disease department at the UCLA School of Medicine – in
23 short, Dr. Vijayan recommends frequent COVID-19 testing and immediate administering of
24 antiviral drugs for the treatment of patients who have at least one risk factor for progression to
25 severe COVID-19 as soon as possible after symptom onset. See Vijayan Decl. (dkt. 20-14) at 10.
26 DISCUSSION
27 Defendants contend that the FAC should be dismissed because Plaintiffs do not have a
1 for COVID-19 while detained at GSA and they are detained at a facility that has not experienced a
2 significant number of COVID-19 cases since August 2023.” See Defs.’ Sur-Reply (dkt. 59-2) at 6;
3 see also Defs.’ Mot. (dkt. 50) at 8. Defendants also contend that the court should “deny Plaintiff’s
4 motion for preliminary injunction for lack of jurisdiction because under a straightforward
5 application of 8 U.S.C. §1252(f)(1), which bars courts from enjoining or restraining the operation
6 of “relevant statutory provisions” of the INA, the Court lacks jurisdiction to issue the class-wide
7 injunctive relief Plaintiffs seek.” Defs.’ Mot. (dkt. 50) at 7 (citing Garland v. Aleman-Gonzalez,
8 596 U.S. 543, 544 (2022)).
9 The court will first note that the government’s reliance on Aleman-Gonzalez’s
10 interpretation of §1252(f)(1) seems misplaced as it relates to this case. Regarding the jurisdiction
11 to enjoin, in Aleman-Gonzalez, the Supreme Court noted that §1252(f)(1) provides that “no court
12 (other than the Supreme Court) shall have jurisdiction or authority to enjoin or restrain the
13 operation of the provisions of part IV of this subchapter, as amended by the Illegal Immigration
14 Reform and Immigrant Responsibility Act of 1996” – however, the Court also added that “the
15 provisions of part IV of subchapter II of the Immigration and Nationality Act . . . charge the
16 Federal Government with the implementation and enforcement of the immigration laws governing
17 the inspection, apprehension, examination, and removal of aliens.” Aleman-Gonzalez, 142 S. Ct.
18 at 2064 (emphasis added). Because it does not appear that Plaintiffs’ request for preliminary
19 injunction would involve anything other than directing specific medical services – to wit, COVID-
20 19 testing and antiviral treatment – for immigration detainees, it does not appear that such an
21 injunction would have the effect of interfering with or otherwise affecting the “enforcement of the
22 immigration laws governing the inspection, apprehension, examination, and removal of aliens,” in
23 any way remotely resembling what was at issue in Aleman-Gonzalez, which involved enjoining
24 the government from detaining individuals pursuant to section §1231(a)(6) for more than 180 days
25 without providing each person a bond hearing. However, those questions do not need to be
26 resolved today because Plaintiffs’ motions for class certification and injunctive relief are due to be
27 denied because the FAC is due to be dismissed without prejudice as discussed below.
1 review for failure to state a claim under 12(b)(6) is generally confined to the contents of the
2 complaint, [] in determining constitutional standing, ‘it is within the trial court’s power to allow or
3 to require the plaintiff to supply, by amendment to the complaint or by affidavits, further
4 particularized allegations of fact deemed supportive of plaintiff’s standing.’” Maya v. Centex
5 Corp., 658 F.3d 1060, 1067 (9th Cir. 2011) (quoting Warth v. Seldin, 422 U.S. 490, 501 (1975),
6 and citing Marder v. Lopez, 450 F.3d 445, 448 (9th Cir. 2006)). A lack of constitutional standing
7 “requires dismissal for lack of subject matter jurisdiction,” whereas a “lack of statutory standing
8 requires dismissal for failure to state a claim.” Maya, 658 F.3d at 1067.
9 A motion to dismiss for lack of standing is brought pursuant to Federal Rule of Civil
10 Procedure 12(b)(1). See Chandler v. State Farm Mut. Auto. Ins. Co., 598 F.3d 1115, 1122 (9th Cir.
11 2010) (noting that, “[b]ecause standing and ripeness pertain to federal courts’ subject matter
12 jurisdiction, they are properly raised in a Rule 12(b)(1) motion to dismiss”). Such a motion can be
13 either facial or factual in nature. See Pride v. Correa, 719 F.3d 1130, 1139 (9th Cir. 2013). “In a
14 facial attack, the challenger asserts that the allegations contained in a complaint are insufficient on
15 their face to invoke federal jurisdiction. By contrast, in a factual attack, the challenger disputes the
16 truth of the allegations that, by themselves, would otherwise invoke federal jurisdiction.” Safe Air
17 For Everyone v. Meyer, 373 F.3d 1035, 1039 (9th Cir. 2004). Here, Defendants have challenged
18 constitutional standing through a facial attack. Constitutional standing consists of three elements:
19 (1) the plaintiff must have suffered an injury in fact; (2) the injury must be fairly traceable to the
20 challenged conduct of the defendant; and (3) the injury is likely to be redressed by a favorable
21 judicial decision. See Lujan v. Defenders of Wildlife, 504 U. S. 555, 559-560 (1992); see also
22 Spokeo, Inc. v. Robins, 578 U.S. 330, 338 (2016). At the pleading stage, “[i]t is the responsibility
23 of the complainant clearly to allege facts demonstrating that he [or she] is a proper party to invoke
24 judicial resolution of the dispute and the exercise of the court’s remedial powers.” Warth v. Seldin,
25 422 U.S. 490, 518 (1975).
26 As it relates to the matter at hand, in order to properly establish an injury in fact, a plaintiff
27 must show that he or she suffered “an invasion of a legally protected interest” that is “concrete and
1 For an injury to be particularized, it “must affect the plaintiff in a personal and individual way, it
2 must be distinct in that it requires that the plaintiff have personally suffered from some actual or
3 threatened injury – further, “[a]n injury must also be concrete.” Robins, 578 U.S. at 339. That is
4 not to say, however, that all types of risk of harm cannot, by definition, satisfy concreteness. Id. at
5 341.
6 Here, Plaintiffs’ first claim for relief asserts the denial of the substantive due process right
7 to reasonable health and safety in government custody. See FAC (dkt. 68) at 17-18. The Fifth
8 Amendment requires the government to provide conditions of reasonable health and safety to
9 people in its custody. Roman v. Wolf, 977 F.3d 935, 943 (9th Cir. 2020); see also Youngberg v.
10 Romeo, 457 U.S. 307 (1982) (substantive due process requires involuntarily committed mental
11 patients to be provide with such services as are necessary to ensure their reasonable safety). The
12 government violates a substantive due process right in this context when: (1) it makes an
13 intentional decision with respect to the conditions under which the plaintiff was confined; (2)
14 those conditions put the plaintiff at substantial risk of suffering serious harm; (3) the government
15 does not take reasonable available measures to abate that risk, even though a reasonable official in
16 the circumstances would have appreciated the high degree of risk involved; and (4) by not taking
17 such measures, the government caused the plaintiff's injuries. Roman, 977 F.3d at 943.
18 Two things must be noted at the threshold. First, the allegations in Plaintiffs’ FAC fall
19 short of making out a claim under all four of the elements of the test set forth in Roman. Plaintiffs
20 have essentially only alleged that if they contract COVID-19 in the future, and if their contracting
21 of COVID-19 is attended with serious symptoms, then Defendants’ might not properly treat them.
22 Putting aside the FAC’s conjecture and speculation, Plaintiffs factual allegations fall well short of
23 establishing any intentional decision on Defendants’ part that would subject them to a substantial
24 risk of suffering serious harm due to which it can be said that Defendants have caused Plaintiffs
25 any injury. Second, when Roman was argued and decided in 2020, the situation regarding
26 COVID-19 was substantially different than what is presently the case (there were no vaccines,
27 protective gear such as masks and hand sanitizer were in short supply, and little was known about
1 We agree with the district court that the Government likely failed to
meet its constitutional duty to provide reasonably safe conditions to
2 Plaintiffs. At the time the injunction issued, Adelanto was so crowded
that social distancing to combat the spread of the novel coronavirus
3 was impossible, detainees had inadequate access to masks, guards
were not required to wear masks, there was not enough soap or hand
4 sanitizer to go around, detainees were responsible for cleaning the
facility with only dirty towels and dirty water, detainees were
5 compelled to sleep with less than six feet of distance between them,
and not all new arrivals were being properly quarantined or tested.
6 The Government was aware of the risks these conditions posed,
especially in light of high-profile outbreaks at other carceral facilities
7 that had already occurred at the time, and yet had not remedied the
conditions. Its inadequate response reflected a reckless disregard for
8 detainee safety.
9 Id.
10 Thus, Plaintiffs’ reliance on Roman’s 2020 holding to make out their 2024 substantive due process
11 claim based the paucity of the allegations they have pleaded in the FAC is misplaced, and the
12 court finds that Plaintiffs’ allegations fall short of stating a Fifth Amendment reasonable health
13 and safety claim under the test set forth in Roman.
14 That said, the court will now turn to the Defendants’ closely-related arguments regarding
15 standing. Conceptually, there is a close correlation between standing and the justiciability issues of
16 mootness and ripeness. Ripeness and mootness can be described as the time dimensions of
17 standing. See Burlington N. R. Co. v. Crow Tribal Council, 940 F.2d 1239, 1242 (9th Cir. 1991)
18 (quoting 13A C. Wright, A. Miller & E. Cooper, Federal Practice and Procedure § 3532.1, at 130
19 (2d ed. 1984)). In general, courts “must determine whether . . . claims demonstrate sufficient
20 ripeness to establish a concrete case or controversy.” Thomas v. Union Carbide Agr. Prods. Co.,
21 473 U.S. 568, 579 (1985) (citing Reg’l Rail Reorganization Act Cases, 419 U.S. 102, 138-139
22 (1974)). Ripeness is a “question of timing” that seeks to prevent “the courts, through premature
23 adjudication, from entangling themselves in abstract disagreements.” Id. In addition to requiring a
24 concrete case or controversy, the ripeness doctrine demands that courts analyze prudential factors:
25 the fitness of the issues for judicial decision and the hardship to the parties of withholding court
26 consideration. Id. at 581. It should be noted at this point that “[i]n measuring whether the litigant
27 has asserted an injury that is real and concrete rather than speculative and hypothetical, the
1 Com’n, 220 F.3d 1134, 1138-39 (9th Cir. 2000) (internal quotation marks omitted). The
2 concreteness element does not force a party “to await the consummation of threatened injury to
3 obtain preventive relief. If the injury is certainly impending, that is enough.” Union Carbide Agr.
4 Prods. Co., 473 U.S. at 581-82 (emphasis added).1 The plaintiff must simply show that he “face[s]
5 ‘a realistic danger of sustaining a direct injury . . .” Anchorage Equal Rights Com’n, 220 F.3d
6 1138-39 (emphasis added) (quoting Babbitt v. United Farm Workers Nat’l Union, 442 U.S. 289,
7 298 (1979)).2 The threat must be genuine. Id. The genuineness of a threat of suit can be shown by
8 a threat’s specificity and a history of similar suits between the parties. Id. For these reasons, “a
9 federal court normally ought not resolve issues ‘involv[ing] contingent future events that may not
10 occur as anticipated, or indeed may not occur at all.’” Clinton v. Acequia, Inc., 94 F.3d 568, 572
11 (9th Cir. 1996) (quoting Union Carbide Agr. Prods. Co., 473 U.S. at 580-81).
12 Thus, “[t]he intersection of ripeness and standing can best be explained in part by the
13 ripeness doctrine’s requirement that adjudication of a particular matter not be dependent upon a
14 contingent event in the future.” In re BofI Holding Shareholder Litig., 2018 U.S. Dist. LEXIS
15 96155, *23 (S.D. Cal., Jun. 7, 2018). “That is so because, if the contingent events do not occur, the
16 plaintiff likely will not have suffered an injury that is concrete and particularized enough to
17 establish the first element of standing.” Alcoa, Inc. v. Bonneville Power Admin., 698 F.3d 774, 793
18 (9th Cir. 2012) (quoting Bova v. City of Medford, 564 F.3d 1093, 1096 (9th Cir. 2009)). Therefore,
19 claims must be dismissed if they are based solely on harms stemming from events that have not
20 yet occurred, and may never occur, because the plaintiffs raising such claims have not “suffered an
21 injury that is concrete and particularized enough to survive the standing/ripeness inquiry.” Alcoa,
22 Inc., 698 F.3d at 793 (quoting Bova, 564 F.3d at 1096-97).
23
24
1 As stated below, this is the essence of the flaw in Plaintiffs’ allegations. That is, their allegations fall short
25 of giving rise to the impression that the threatened injury of which they complain is “certainly impending.”
26
2 Here, the court is unpersuaded that Plaintiffs’ allegations amount to establishing “a realistic danger.”
Instead, the danger manifest in their allegations is speculative and contingent at most because they have only
27 alleged that if they contract COVID-19 in the future, and if it is attended with serious symptoms, then
Defendants’ might not elect to treat them with antiviral medications, which might subject them to serious
1 Here, the essence of Plaintiffs’ Fifth Amendment claim regarding the substantive due
2 process right to reasonable health and safety in government custody rests on too many
3 contingencies for the court to conclude that any injury is sufficiently concrete and particularized to
4 survive the necessary standing / ripeness inquiry. At bottom, Plaintiffs appear to seek the court’s
5 intervention in micromanaging Defendants’ medical policies – and they seem to request that the
6 court undertake that task in the abstract; that is, without having alleged that there exists a realistic
7 danger of Plaintiffs’ ever suffering any direct injury. As mentioned, Plaintiffs have only really
8 alleged that (1) they’re not tested frequently enough for COVID-19; (2) that if they contract
9 COVID-19 they might develop serious symptoms due to their underlying health conditions; (3)
10 that if they contract COVID-19 and develop serious symptoms, Defendants might not treat them in
11 the most effective way – which they contend should involve administering an antiviral dose at a
12 time close to the manifestation of the symptoms. Plaintiffs simply have not alleged enough facts to
13 take their claim beyond the realm of speculation and conjecture. Plaintiffs have not alleged any
14 facts that might show the genuineness or specificity of the thereat of the alleged dangers of which
15 they complain (for example, by detailing a history of others detained at their facility who have
16 actually suffered direct injury due to Defendants’ alleged failures in testing for and properly
17 treating COVID-19). Thus, Plaintiffs’ first claim must be dismissed.
18 Through their second claim, and based on the same set of allegations, Plaintiffs plead
19 another substantive due process claim to the effect that their civil confinement has risen to the
20 level of punishment because the California Department of Corrections and Rehabilitation makes
21 frequent COVID-19 testing and antiviral covid medications available as part of the prison medical
22 care it provides while Defendants reportedly do not provide frequent testing or make such
23 medications available at GSA. See FAC (dkt. 68) at ¶¶ 54, 77-81. The gist of Plaintiffs’ claim here
24 seems to be that “Defendants’ failure to provide Paxlovid is unconstitutional punishment.” See
25 Pls.’ Mot. for Prelim. Inj. (dkt. 20) at 18-19.
26 “As civil detainees retain greater liberty protections than individuals detained under
27 criminal process, [] and pre-adjudication detainees retain greater liberty protections than convicted
1 entitled to protections at least as great as those afforded to a civilly committed individual and at
2 least as great as those afforded to an individual accused but not convicted of a crime.” Jones v.
3 Blanas, 393 F.3d 918, 932 (9th Cir. 2004) (citing Youngberg v. Romeo, 457 U.S. 307, 321-24
4 (1982) (civilly committed individuals); and, Bell v. Wolfish, 441 U.S. 520, 535-36 (1979) (pretrial
5 detainees)). Thus, an individual detained under civil process – like an individual accused but not
6 convicted of a crime – cannot be subjected to conditions that amount to punishment. Id. In this
7 regard, “punitive conditions may be shown (1) where the challenged restrictions are expressly
8 intended to punish, or (2) where the challenged restrictions serve an alternative, non-punitive
9 purpose but are nonetheless excessive in relation to the alternative purpose, or are employed to
10 achieve objectives that could be accomplished in so many alternative and less harsh methods.” Id.
11 (internal quotations and citations omitted).
12 There are two problems with Plaintiffs’ second claim. First, Plaintiffs’ FAC does not
13 present allegations that would satisfy the two-part test set forth above. Plaintiffs appear to have
14 fallen short of stating a substantive due process claim for punitive civil detention in that they have
15 not plausibly alleged that Defendants’ failure to offer Paxlovid upon the manifestation of what are
16 believed to be, or are in fact, COVID-19 symptoms constitute “restrictions [that] are expressly
17 intended to punish,” or that they are excessive or are employed to achieve objectives that could be
18 effectuated by less harsh methods. Jones, 393 F.3d at 932. More importantly, however, for the
19 reasons stated above with respect to the first claim, Plaintiffs have not alleged any injury or danger
20 that is non-contingent and sufficiently concrete and particularized to survive the standing/ripeness
21 inquiry.
22 //
23 //
24 //
25 //
26 //
27 //
1 CONCLUSION
2 For all of these reasons, the court finds that Plaintiffs’ claims must be dismissed because
3 || they are based solely on harms stemming from events that have not yet occurred and may very
4 || well never occur. Thus, Defendants’ Motion to Dismiss (dkt. 50) is GRANTED. Because it is not
5 clear that leave to amend 1s incapable of remedying the defects described herein, Plaintiffs’ FAC
6 || (dkt. 68) is DISMISSED with leave to amend. Plaintiffs shall have 60 days within which to file a
7 Second Amended Complaint. Because Plaintiffs’ operative complaint has been dismissed, their
8 || Motions for Preliminary Injunction (dkt. 20) and Class Certification (dkt. 21) are DENIED.
9 IT IS SO ORDERED.
10 Dated: May 20, 2024
a
ROBERT M. ILLMAN
13 United States Magistrate Judge
15
16
it
4 18
19
20
21
22
23
24
25
26
27
28